New Era for T Cell Immunotherapy
Human T cells have been hard to transfect with other methods, especially for plasmids.
With Celetrix electroporation, T cells can be transfected any time from the fresh PBMC stage to the stimulated or cultured stage. The Celetrix technology can achieve high transfection efficiency while maintaining high level of cell survival and expansion, allowing immunotherapy applications such as CAR, TCR-T generation and CRISPR knock-down of T cell genes.
Human PBMC transfection with GFP plasmid
Transfection efficiency with GFP plasmid after 24 hours is over 80%
Human PBMC transfection of CAR-T2A-GFP with SB transposon
Human PBMC CAR expression at 65.9% after 14 days.
Cells form clusters and proliferate similar to un-electroporated cells.
Electroporation—– The Future of CAR-T Therapy
|
Electroporation |
Viral vectors |
|
| Efficiency | High | Low |
| Cost | Low | Very High |
| Time | Short | Long |
| Side effects | Simple | Gene insertion problem |
Viral vectors have been the predominant delivery vehicles in immunotherapy, since the other existing electroporation methods fared poorly with immune cells.
The new high-performance Celetrix technology swiftly electroporates unstimulated PBMC cells and supports fast cell expansion, enabling clinical T cell transfection for CAR-T therapy.